Saturday 17 October 2026
Export UPC’s income statement to Excel — free account
Universe Pharmaceuticals INC
UPC Healthcare Drug Manufacturers Specialty & Generic
Universe Pharmaceuticals INC’s revenue for fiscal 2025 (year ended September 2025) was $17.9 million, down 22.4% from fiscal 2024.
3.97
0.18
−4.34%
Follow UPC
| Mar '26 | Sep '25 | Mar '25 | Sep '24 | Older periods | |
|---|---|---|---|---|---|
P/E ratio |
— | — | — | — |
+8 more quarters Free account |
EV/Sales |
— | — | — | — | |
EV/FCF |
— | — | — | — | |
Quick Ratio |
3.75 | 3.71 | 2.60 | 2.37 | |
Current Ratio |
4.05 | 4.07 | 2.78 | 2.54 | |
Net Debt/EBITDA |
0.00 | 0.00 | 0.00 | 0.00 | |
Debt/Assets |
13.37% | 13.36% | 9.58% | 11.76% | |
Debt/Equity |
0.17 | 0.16 | 0.14 | 0.18 | |
Asset Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF/Net income |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex/Depreciation |
(1.39) | (0.50) | (0.49) | (0.50) | |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | |
Free Cash Flow Yield |
— | — | — | — | |
Operating CF per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Free Cash Flow per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Cash per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Shareholders Equity per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Free Cash Flow |
(4.62) | (5.31) | 2.43 | (9.75) | |
Working Capital |
41.56 | 40.43 | 41.61 | 31.33 | |
Capital Expenditures |
(0.32) | (0.26) | (0.13) | (0.24) | |
Net Current Asset Value |
39.39 | 40.43 | 39.54 | 29.19 | |
EV/EBIT |
— | — | — | — | |
Capex to Sales |
0.00 | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Receivables |
18.26 | 14.14 | 15.52 | 16.88 | |
Average Payables |
5.76 | 3.13 | 9.32 | 4.00 | |
Average Inventory |
2.68 | 2.77 | 3.22 | 1.97 | |
Average Assets |
60.45 | 55.51 | 75.52 | 63.75 | |
Average Common Equity |
41.19 | 42.03 | 51.16 | 45.97 |
Columns are period end dates